Transcatheter aortic valve implantation in patients with bicuspid aortic valve: A patient level multi-center analysis

Yousef, Altayyeb; Simard, Trevor; Webb, John G.; Rodés‐Cabau, Josep; Costopoulos, Charis; Kochman, Janusz; Hernández-García, José M.; Chiam, Paul T.L.; Welsh, Robert C.; Wijeysundera, Harindra C.; García, Eulogio; Ribeiro, Henrique Barbosa; Latib, Azeem; Huczek, Zenon; Shanks, Miriam; Testa, Luca; Farkouh, Michael E.; Dvir, Danny; Velianou, James L.; Lam, Buu Khanh; Pourdjabbar, Ali; Glover, Christopher; Hibbert, Benjamin; Labinaz, Marino

doi:10.1016/j.ijcard.2015.04.066

Cited by 90 publications

(68 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The presence of raphes, calcifications and difficulties in accurate positioning of the THV contribute to the risk of PVL in BAV patients. Although the incidence of PVL differed across studies with BAV patients, the occurrence of PVL grade ≥ 2 was generally higher than TAV patients [8,23,24]. Similar results were found in our reported cohort.…”

Section: Discussionsupporting

confidence: 88%

Hemodynamic changes after transcatheter aortic valve implantation during sequential follow-ups in patients with bicuspid aortic valve compared with tricuspid aortic valve

et al. 2017

View full text Add to dashboard Cite

[-0.25, 5.00] mm Hg, p = 0.57 at 1 month; p = 0.21 at 3 months; 0.96 ± 7.81 vs. 1.53 ± 5.85 mm Hg, p = 0.79 at 6 months; 2.25] vs. 3.00 [-0.50, 7.50] mm Hg, p = 0.07 at 1 year). Moreover, the incidence of ≥ mild PVL was not significantly different in patients with p = 0.14 at 1 month; 45.83% vs. 27.27%, p = 0.19 at 3 months; 30.00% vs. 23.53%, p = 0.89 at 6 months; 30.00% vs. 17.65%, p = 0.56 at 1 year). Conclusions: TAVI is effective and applicable in BAV anatomy with sustained and acceptable mid--term prosthesis hemodynamic performance. (Cardiol J 2017; 24, 4: 350-357)

show abstract

Section: Discussionsupporting

confidence: 88%

Hemodynamic changes after transcatheter aortic valve implantation during sequential follow-ups in patients with bicuspid aortic valve compared with tricuspid aortic valve

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Several reports have documented increased paravalvular leak rates and increased use of permanent pacemaker when TAVI was used to treat bicuspid aortic valve stenosis (26)(27)(28). Yousef et al (27) and Mylotte et al (26) separately reported the rates of paravalvular leak of 2+ or greater as 30.8% and 28.4% respectively.…”

Section: Discussionmentioning

confidence: 99%

Transcatheter aortic valve implantation in Asia

Hon

Tay

2017

Ann. Cardiothorac. Surg.

View full text Add to dashboard Cite

The use of transcatheter aortic valve implantation (TAVI) to treat severe symptomatic aortic valve stenosis has increased exponentially in the last decade. This rapid expansion was seen predominantly in Western developed nations and has been fuelled by favorable results reported from a plethora of well-publicized randomized controlled trials, large retrospective series and national registries. Now, TAVI has become the standard of care for inoperable patients and an alternative to open surgery in patients who are at intermediate to high risk for open surgery. Notwithstanding these positive results, Asia has been relatively slow to adopt this technology despite a potentially large patient pool. Unique features of Asian medical environments and differences in Asian anatomy affecting TAVI uptake in Asia will be discussed. This article serves to outline the various challenging aspects of disseminating TAVI in Asian countries.

show abstract

“…3 Based on this early success, operators have expanded the scope of eligible TAVI candidates to an ever growing list of aortic valve pathologies. 4 Indeed, TAVI is often used in patients with low-flow low-gradient severe AS, 5 stenotic bicuspid aortic valves (BAVs), 6 and in patients with failing bioprostheses. 7 Recently, increasing numbers of reports of TAVI being Manuscripts were identified by reviewing the titles and abstracts of studies with selection performed by 2 coauthors and conflicts resolved by consensus.…”

mentioning

confidence: 99%

Transcatheter Aortic Valve Implantation (TAVI) for Native Aortic Valve Regurgitation　― A Systematic Review ―

Yousef

MacDonald

Simard

et al. 2018

Circ J

Self Cite

View full text Add to dashboard Cite

Background: Transcatheter aortic valve implantation (TAVI) has become the standard of care for management of high-risk patients with aortic stenosis. Limited data is available regarding the performance of TAVI in patients with native aortic valve regurgitation (NAVR). Methods and Results:We performed a systematic review from 2002 to 2016. The primary outcome was device success as per VARC-2 criteria. Secondary endpoints included procedural complications, and 30-day and 1-year mortality rates. A total of 175 patients were included from 31 studies. Device success was reported in 86.3% of patients -with device failure driven by moderate aortic regurgitation (AR ≥3+) and/or need for a second device. Procedural complications were rare, with no procedural deaths, myocardial infarctions or annular ruptures reported. Procedural safety was acceptable with a low 30-day incidence of stroke (1.5%). The 30-day and 1-year overall mortality rates were 9.6% and 20.0% (cardiovascular death, 3.8% and 10.1%, respectively). Patients receiving 2nd-generation valves demonstrated similar safety profiles with greater device success compared with 1st-generation valves (96.2% vs. 78.4%). This was driven by the higher incidence of second-valve implantation (23.4% vs. 1.7%) and significant paravalvular leak (8.3% vs. 0.0%).Conclusions: TAVI demonstrates acceptable safety and efficacy in high-risk patients with severe NAVR. Second-generation valves may afford a similar safety profile with improved device success. Dedicated studies are needed to definitively establish the efficacy of TAVI in this population.

show abstract

Transcatheter aortic valve implantation in patients with bicuspid aortic valve: A patient level multi-center analysis

Cited by 90 publications

References 24 publications

Hemodynamic changes after transcatheter aortic valve implantation during sequential follow-ups in patients with bicuspid aortic valve compared with tricuspid aortic valve

Hemodynamic changes after transcatheter aortic valve implantation during sequential follow-ups in patients with bicuspid aortic valve compared with tricuspid aortic valve

Transcatheter aortic valve implantation in Asia

Transcatheter Aortic Valve Implantation (TAVI) for Native Aortic Valve Regurgitation　― A Systematic Review ―

Contact Info

Product

Resources

About

Transcatheter aortic valve implantation in patients with bicuspid aortic valve: A patient level multi-center analysis

Cited by 90 publications

References 24 publications

Hemodynamic changes after transcatheter aortic valve implantation during sequential follow-ups in patients with bicuspid aortic valve compared with tricuspid aortic valve

Hemodynamic changes after transcatheter aortic valve implantation during sequential follow-ups in patients with bicuspid aortic valve compared with tricuspid aortic valve

Transcatheter aortic valve implantation in Asia

Transcatheter Aortic Valve Implantation (TAVI) for Native Aortic Valve Regurgitation ― A Systematic Review ―

Contact Info

Product

Resources

About

Transcatheter Aortic Valve Implantation (TAVI) for Native Aortic Valve Regurgitation　― A Systematic Review ―